ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 454,40
0,17%
DAX
18 772,85
0,50%
Brent Oil
82,705
-1,48%
Bitcoin
60 562,99
-3,94%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Matinas Biopharma Holdings Inc (MTNB)

  7. Matinas Biopharma Holdings Inc (MTNB) Actualités

MTNB Matinas Biopharma Holdings Inc

0,1721
-0,0046 (-2,60%)
Dernière mise à jour : 20:21:17
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Matinas Biopharma Holdings Inc MTNB AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0046 -2,60% 0,1721 20:21:17
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,1767 0,1673 0,177 0,1767
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
09/5/202422:06EDGAR2Form 8-K - Current report
09/5/202422:05GLOBEMatinas BioPharma Reports First Quarter 2024 Financial..
09/5/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202414:00GLOBEMatinas BioPharma’s LNC Platform for the Delivery of Small..
02/5/202413:00GLOBEMatinas BioPharma to Webcast Conference Call to Discuss..
30/4/202414:00GLOBEIn Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in..
03/4/202414:30GLOBEMatinas BioPharma Prices $10 Million Registered Direct..
27/3/202421:05GLOBEMatinas BioPharma Reports 2023 Financial Results and..
25/3/202413:00GLOBEMatinas BioPharma Announces Positive in vivo Safety Data..
22/3/202414:15GLOBEThree Patients with Invasive Fusarium Infection in Matinas..
22/3/202411:30GLOBEMatinas BioPharma Regains Compliance with NYSE American..
26/2/202414:05EDGAR2Form 8-K - Current report
26/2/202414:00GLOBEMatinas BioPharma Provides Positive Outcomes Update on the..
20/2/202413:35EDGAR2Form 8-K - Current report
20/2/202413:30GLOBEMatinas BioPharma Successfully Reaches Agreement with FDA..
09/1/202413:30EDGAR2Form 8-K - Current report
03/1/202413:00GLOBEMatinas BioPharma to Present at Biotech Showcase 2024
27/12/202313:40EDGAR2Form 8-K - Current report
27/12/202313:30GLOBEMatinas BioPharma Demonstrates in vivo Biological Activity..
21/12/202313:40EDGAR2Form 8-K - Current report
21/12/202313:30GLOBEMatinas BioPharma Provides Update to MAT2203 Regulatory and..
16/12/202303:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202303:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202303:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202303:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202303:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202303:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202313:30EDGAR2Form 8-K - Current report
09/11/202323:25EDGAR2Form 8-K - Current report
08/11/202322:06EDGAR2Form 8-K - Current report
08/11/202322:05GLOBEMatinas BioPharma Reports Third Quarter 2023 Financial..
08/11/202322:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:30GLOBEMatinas BioPharma Announces Positive in vivo Efficacy..
03/11/202321:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202322:20EDGAR2Form 8-K - Current report
01/11/202312:00GLOBEMatinas BioPharma to Webcast Conference Call to Discuss..
11/10/202316:25APSBiotech Catches Massive Premarket Bid
11/10/202313:30GLOBEPatient with Candida krusei Infection in Matinas BioPharma’s..
28/9/202313:00GLOBEMatinas BioPharma to Present at Two Investment Conferences..
27/9/202313:00GLOBEMatinas BioPharma to Feature MAT2203 in a Pipeline..
22/9/202323:25EDGAR2Form 8-K - Current report
22/9/202323:25GLOBEMatinas BioPharma Announces Notification of NYSE American..
21/9/202315:35GLOBEDawson James Securities Announces October Date for 8th..
20/9/202313:30EDGAR2Form 8-K - Current report
19/9/202323:25EDGAR2Form DEF 14A - Other definitive proxy statements
08/9/202323:15EDGAR2Form PRE 14A - Other preliminary proxy statements
06/9/202313:00GLOBEMatinas BioPharma to Participate in the H.C. Wainwright..
22/8/202313:30GLOBEMatinas BioPharma Announces Publication of Results from the..
09/8/202322:06EDGAR2Form 8-K - Current report
09/8/202322:05GLOBEMatinas BioPharma Reports Second Quarter 2023 Financial..

Dernières Valeurs Consultées

AMEX
MTNB
Matinas Biopharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés